Neurocrine To Present Data From Movement Disorder Treatments For TD & Parkinson's Disease

Neurocrine Biosciences Inc. (NBIX) said that it will present new data from its movement disorder treatments for tardive dyskinesia or TD and Parkinson's disease at the International Parkinson and Movement Disorder Society's or MDS Virtual Congress 2021 being held September 17-22, 2021.

A long-term Phase 3 data from KINECT 4 study demonstrated robust clinically meaningful reductions in Tardive Dyskinesia symptoms at 48 weeks with once-daily INGREZZA (valbenazine) capsules. Data show some patients met the criteria for tardive dyskinesia remission within one year of once-daily INGREZZA treatment.

In addition, an oral presentation will introduce a new pooled data analysis from the BIPARK-1 and BIPARK-2 Phase 3 studies evaluating effects on sleep of ONGENTYS (opicapone) compared to placebo in people with Parkinson's disease and motor fluctuations.

Further, a poster presentation will feature new data from a Phase 1 open-label study assessing the effect of ONGENTYS on levodopa levels when administered as a once-daily add-on therapy to oral levodopa/carbidopa extended-release capsules, the first study to evaluate both formulations together.

The new pooled analysis of two phase 3 studies found treatment with ongentys as an add-on to levodopa/carbidopa decreased the frequency of nighttime awakenings and total wake time compared to placebo in people with parkinson's disease.

The first study, which evaluates ongentys as an add-on therapy to oral levodopa/carbidopa extended-release capsules, resulted in more consistent levodopa levels throughout the day and night.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Drug major Pfizer has again expanded the earlier two recalls of its anti-smoking Drug Chantix (Varenicline) in the form of tablets, to now include all the lots, for the potential presence of nitrosamine impurity, N-Nitroso- varenicline, at or above the FDA interim acceptable intake limit (ADI), the U.S. Food and Drug Administration or FDA said in a statement. Department store chain Sears is closing down its last store located in its home state of Illinois, CNBC reported. The company, which was founded in Chicago in 1892, plans to shut the shop, located in Simon Property Group's Woodfield Mall, on November 14. Sears' parent company, Transformco, which also manages the real estate, said it plans to maximize the value of the Woodfield Mall property and Amazon said over 1 million people have applied for a job at the tech major as part of its Career Day 2021. Job seekers from more than 170 countries have participated in the virtual event. In addition, more than 2,000 Amazon recruiters offered 30,000 individual career coaching sessions with participants in a single day.
Follow RTT